A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [ 177 Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.

Jie ZangGuochang WangTianzhi ZhaoHuipan LiuXiuting LinYun YangZezhong ShaoChao WangHaojun ChenYue ChenZhaohui ZhuWeibing MiaoXiaoyuan ChenJingjing Zhang

Published in: European journal of nuclear medicine and molecular imaging (2023)

gov/ct2/show/NCT05613738.

Keyphrases

image quality
computed tomography
dual energy
contrast enhanced
monte carlo
magnetic resonance